Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (2016-2017 northern hemisphere formulation)
- Development stage
- Approved
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The "flu vaccine 2016-2017" refers to the set of inactivated and recombinant vaccines formulated for the prevention of influenza during the 2016–2017 northern hemisphere flu season. These vaccines were designed to protect against four specific strains of influenza virus as recommended by the World Health Organization and U.S. health authorities. The quadrivalent formulations included two type A strains (H1N1 and H3N2) and two type B lineages (Victoria and Yamagata). Trivalent versions contained only one B lineage. Most vaccines were inactivated split-virus or subunit types; some used adjuvants like MF59 to enhance immune response in older adults. The primary mechanism is induction of strain-specific neutralizing antibodies against hemagglutinin surface proteins.
- Brand names
- Fluzone QuadrivalentFLUADFluarixFluLaval
- Other names
- flu vaccine 2016-2017seasonal influenza vaccine 2016-2017
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (2016-2017 northern hemisphere formulation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (2016-2017 northern hemisphere formulation).